RINVOQ (upadacitinib) Tablets
RINVOQ is a prescription medicine used to treat adults with moderate to severe ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with ulcerative colitis. Brand Name: RINVOQ (upadacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2019. FDA approved upadacitinib (brand name RINVOQ) is not (yet) registered or available in India but on request Indian patient can buy RINVOQ at the lowest price.
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
RINVOQ (upadacitinib) extended-release tablets
Upadacitinib is used alone or with other medications to treat rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) in people who are unable to take or have not responded well to one or more tumor necrosis factor (TNF) inhibitor medication(s).
RINVOQ is a prescription medicine that is a Janus kinase (JAK) inhibitor. RINVOQ is used:
• to treat adults with moderate to severe rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
• to treat adults with active psoriatic arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
• to treat adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.
• to treat adults with moderate to severe ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
• to treat adults with moderate to severe Crohn’s disease when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
• to treat adults with active ankylosing spondylitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
• to treat adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation whe
Upadacitinib is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and axial spondyloarthritis.
Upadacitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.
Upadacitinib was approved in January 2022, by the FDA for treating adults and children twelve years of age and older with moderate to severe treatment refractory atopic dermatitis.
Upadacitinib was approved in March 2022, by the FDA for treating adults with moderately to severely active ulcerative colitis who did not respond to treatment with anti-TNF drugs (e.g. Infliximab).[16]
Upadacitinib was approved in February 2023, by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with moderately to severely active Crohn’s disease.
In April 2023, upadacitinib was approved in the EU for the treatment of moderately to severely active Crohn’s disease in adults.
In May 2023, the FDA approved upadacitinib for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers.
Drug (Brand / Generic): RINVOQ / upadacitinib
Current Indications: tumor necrosis factor (TNF)
Marketed by:: AbbVie Inc.
Approval Date: 2019
Dosage forms and strengths of RINVOQ (upadacitinib) extended-release tablets
Extended-release tablets: 15 mg, 30 mg, and 45 mg
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ RINVOQ (upadacitinib) Tablets ”. FDA approved upadacitinib (brand name RINVOQ) is not (yet) registered or available in India but on request Indian patient can buy RINVOQ at the lowest price. Confirmation of the order for RINVOQ (upadacitinib) Tablets will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to FDA approved upadacitinib (brand name RINVOQ) India.
For personal use, get access to FDA approved upadacitinib (brand name RINVOQ) India. On request, We have imported and delivered Anti-cancer medicines to following cities in India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
RINVOQ Sourcing & Delivery
Alleviare India specializes in sourcing and supplying RINVOQ, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of RINVOQ in India.
How much does RINVOQ cost in the India?
Kindly reach out to us for RINVOQ (upadacitinib) Tablets price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import RINVOQ to India?
To import upadacitinib RINVOQ, patients or government hospitals can place an order on behalf of the patients.
The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is RINVOQ available in India?
RINVOQ upadacitinib is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of RINVOQ (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for RINVOQ availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is upadacitinib available in India?
Yes, FDA approved upadacitinib (brand name RINVOQ) is not (yet) registered or available in India but on request Indian patient can buy RINVOQ at the lowest price. Alleviare will help patient / doctor to get in India.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand RINVOQ (upadacitinib) Tablets. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to RINVOQ (upadacitinib) Tablets , they can inquire and find further information by sending their inquiries to ALS.
